# A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

> **NCT00687362** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Infliximab

## Key facts

- **NCT ID:** NCT00687362
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-30
- **Primary completion:** 2008-11-11
- **Final completion:** 2008-11-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687362, "A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00687362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*